Octreotide Injection Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 50 mcg/mL, 100 mcg/mL, 200,cg/mL, 500 mcg/mL
Reference Brands: Sandostatin.(EU & US)
Category:
Oncology Cancer Care
Octreotide Injection (50 mcg/mL, 100 mcg/mL, 200 mcg/mL, 500 mcg/mL) is used in oncology to manage symptoms and control growth in carcinoid tumors, gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and acromegaly. Available in both U.S. and EU, this somatostatin analog is administered via subcutaneous or IV injection. It helps regulate hormone secretion, improving symptoms and tumor control in oncology patients, making it a key product in oncology B2B distribution.
Octreotide Injection is available in Injection
and strengths such as 50 mcg/mL, 100 mcg/mL, 200,cg/mL, 500 mcg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Octreotide Injection is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Octreotide Injection can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Octreotide Injection 50 mcg/mL, 100 mcg/mL, 200 mcg/mL, and 500 mcg/mL is used to manage symptoms and control the growth of neuroendocrine tumors in oncology. Primarily indicated for carcinoid tumors, GEP-NETs, and acromegaly, Octreotide works by mimicking the effects of somatostatin, regulating hormone production. It is available in subcutaneous or IV formulations and is a vital part of oncology B2B distribution in both the U.S. and EU, ensuring better symptom management and tumor control for patients suffering from neuroendocrine malignancies and related conditions.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing